While GLP-1 drugs can aid weight loss, their high cost and side effects present challenges. The drugs could be beneficial to people with excess visceral fat who are at risk of chronic illnesses. Most insurance providers do not cover GLP-1s and they are intended for lifetime use. Another problem is identifying who needs GLP-1s, as the primary metric for determining candidates is weight, despite BMI being an inaccurate measure of body fat and the detrimental visceral fat.
NHS Princess Alexandra Hospital – how attack exposure technology strengthened cybersecurity
The UK NHS Trust Princess Alexandra Hospital has discovered twice as many unknown devices on its network since moving to attack exposure technology. The tool
